🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

TEVA TEVA

Company Profile ↓
$34.72
+125.75% 1Y
Mkt Cap$43.62B
P/E28.69
P/B5.51
52W High$36.34
52W Low$15.38
Book Value$6.30
EPS (TTM)$1.21

Company Overview

TEVA (TEVA) is a publicly traded company listed on with a market capitalization of $43.62B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.8%, reflecting efficient use of shareholder capital.

Healthy Margins

Operating margin of 22.9% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $17.26B (+4.3% YoY); net profit $1.41B.
  • Trailing 12 Months Year-on-year growth — revenue +4.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR -1.3%, profit CAGR -1.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-1.29%
1 Year:4.31%

Compounded Profit Growth

5 Years:-1.18%
1 Year:-

Stock Price Performance

1 Year:+125.75%
6 Months:-4.22%
3 Months:-3.18%
1 Month:+0.20%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 92% of range
$15.38 $36.34
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.94 · Neutral
Price Performance
1M+0.20%
3M-3.18%
6M-4.22%
1Y+125.75%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -1.3% CAGR over 5 years.
  • Earnings shrank at -1.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
28.69
Industry PE
-
Forward P/E est.
29.03
PEG Ratio
-
Book Value
$6.30
Price to Book
5.51
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-1.29%
Profit 5Y
-1.18%
Revenue (YoY)
4.31%
Earnings (YoY)
-

Profitability & Returns

ROCE
14.48%
ROE
17.83%
ROA
3.46%
Profit Margin
8.17%
Op Margin
22.90%
Gross Margin
51.79%
EPS (Latest Qtr)
$-0.49
EPS (TTM)
$1.21

Balance Sheet & Liquidity

Debt/Equity
2.16
Quick Ratio
0.80
Current Ratio
1.04
Debt
$17.09B
Total Assets
$39.86B
Current Assets
$13.76B
Working Capital
$490.00M

Ownership

Promoter Holding
0.00%
Chg in Prom Hold
-
FII / Inst Holding
62.86%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$17.26B
EBITDA
$3.14B
Free Cash Flow
$1.15B
Operating Cash Flow
$1.65B
Shares Outstanding
1.26B
Gross Margin
51.79%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----5.65B5.72B5.62B5.40B4.92B4.55B4.38B4.42B4.15B4.18B4.09B4.47B4.36B3.87B3.98B4.45B3.98B3.91B3.89B3.66B3.79B3.60B-3.66B3.88B3.85B3.82B4.16B4.33B--4.18B4.48B4.71B3.98B4.14B
Cost of Revenue -----------------------------------2.07B2.18B2.06B2.01B1.99B
Gross Profit 2.79B2.88B2.80B3.39B2.77B2.80B2.60B2.44B2.31B2.03B1.98B1.97B1.86B1.89B1.83B1.96B2.06B1.76B1.85B2.05B1.88B1.87B1.79B1.74B1.79B1.67B-1.58B1.80B1.85B1.77B2.02B2.15B--2.10B2.30B2.66B1.97B2.15B
Operating Expenses -----------------------------------1.20B1.23B1.39B1.21B2.00B
Operating Income ----895.00M-5.74B378.00M-1.52B-14.00M16.00M-134.00M-644.00M-81.00M-191.00M173.00M-4.34B-434.00M582.00M623.00M-713.00M-967.00M424.00M-940.00M-13.00M-654.00M344.00M-218.00M-5.00M-51.00M--899.00M1.07B1.27B759.00M149.00M
EBITDA -----------------------------------657.00M1.10B632.00M877.00M-19.00M
Interest Expense -----------------------------------203.00M209.00M292.00M201.00M195.00M
Pretax Income -----------------------------------203.00M646.00M80.00M437.00M-455.00M
Tax Provision ------------------------------------78.00M214.00M-390.00M67.00M121.00M
Net Income ----645.00M-5.97B595.00M-11.54B1.12B-176.00M-208.00M-2.89B-105.00M-689.00M-314.00M110.00M69.00M140.00M-4.35B150.00M77.00M207.00M292.00M-955.00M-251.00M61.00M-1.30B-220.00M-872.00M69.00M-139.00M-846.00M-437.00M--282.00M433.00M480.00M369.00M-576.00M
Diluted EPS 0.620.200.35-1.020.57-5.940.52-11.411.03-0.24-0.27-2.85-0.10-0.63-0.290.100.060.13-3.970.140.070.190.26-0.86-0.230.05-1.17-0.20-0.780.06-0.12-0.75-0.39--0.240.370.410.31-0.49
R&D Expense --------54.00M--------------54.00M----------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 19.65B21.90B21.85B18.27B16.89B16.66B15.88B14.93B15.85B16.54B17.26B
Cost of Revenue -------7.95B8.20B8.48B8.32B
Gross Profit 11.36B11.65B10.62B8.30B7.54B7.73B7.59B6.97B7.64B8.06B8.94B
Operating Expenses -------4.28B4.45B4.70B4.99B
Operating Income 3.35B2.15B-17.48B-1.64B-443.00M-3.57B1.72B2.69B3.19B3.36B3.95B
EBITDA --------925.00M1.56B777.00M3.14B
Interest Expense -------930.00M1.03B1.00B916.00M
Pretax Income --------3.16B-624.00M-1.28B1.22B
Tax Provision --------643.00M-7.00M676.00M-180.00M
Net Income 1.59B329.00M-16.27B-2.15B-999.00M-3.99B417.00M-2.45B-559.00M-1.64B1.41B
Diluted EPS 1.820.07-16.26-2.35-0.91-3.640.38-2.12-0.50-1.451.21
R&D Expense 35.00M422.00M175.00M114.00M---98.00M---

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Jan 2016Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Dec 2024Dec 2025
Total Assets ---93.06B70.61B60.68B57.47B50.64B-45.93B44.25B44.01B43.46B43.10B42.09B43.48B39.33B40.75B
Current Assets -----------12.05B---12.48B12.55B13.95B
Cash & Equivalents 2.23B6.95B-988.00M963.00M1.78B1.98B2.18B---2.80B---3.23B3.30B3.56B
Inventory -----------3.83B---4.02B3.01B3.18B
Receivables -----------3.70B---3.41B3.06B3.71B
Total Liabilities ---58.06B51.87B44.89B42.41B39.58B-36.12B34.75B35.41B34.96B35.51B34.71B35.35B33.61B32.83B
Current Liabilities ---18.49B17.92B14.32B13.67B13.16B---11.47B---12.25B12.80B13.46B
Long Term Debt ---32.52B28.83B------19.10B---18.16B16.00B14.99B
Total Debt -----------21.56B---20.15B18.08B17.09B
Total Equity 23.36B29.93B29.93B33.34B17.36B14.71B13.97B10.03B-9.81B9.51B7.80B8.50B7.59B7.39B7.51B5.37B7.91B
Shares Outstanding -----------1.22B---1.23B1.24B1.26B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 5.54B3.89B2.23B2.45B748.00M1.22B-1.59B1.37B1.25B1.65B
Investing Cash Flow -5.57B-34.41B3.45B1.87B1.35B863.00M-656.00M968.00M792.00M737.00M
Financing Cash Flow 4.80B25.22B-5.75B-3.35B-1.93B-1.89B--1.49B-1.91B-1.79B-2.15B
Capital Expenditure -772.00M-901.00M-874.00M-651.00M-525.00M-578.00M--548.00M-526.00M-498.00M-501.00M
Free Cash Flow 4.77B2.99B1.35B1.79B223.00M638.00M-1.04B842.00M749.00M1.15B
Net Change in Cash -------759.00M423.00M247.00M235.00M
Share Buybacks 439.00M00--------

Ratios (Annual)

Figures in %.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 57.8%53.2%48.6%45.4%44.6%46.4%47.8%46.7%48.2%48.7%51.8%
Operating Margin % 17.1%9.8%-80.0%-9.0%-2.6%-21.4%10.8%18.0%20.2%20.3%22.9%
Net Margin % 8.1%1.5%-74.4%-11.8%-5.9%-24.0%2.6%-16.4%-3.5%-9.9%8.2%
ROE % 5.3%1.0%-93.7%-14.6%-7.2%-39.8%--31.3%-7.4%-30.5%17.8%
ROCE % -2.9%-33.2%-3.5%-1.0%-9.5%-8.3%10.2%12.7%14.5%

Shareholding Pattern

Insiders
0.00%
Institutions
62.86%
Public Float
62.86%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TEVA

Yahoo Finance Sun, 02 Aug 2026

Why Teva Pharmaceutical Stock Surged This Week

Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst.

Yahoo Finance Sun, 02 Aug 2026

Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14

Teva Pharmaceutical is set to list its ordinary shares on Sept. 14.

Yahoo Finance hu, 30 Jul 2026

Teva (TEVA) Lifts UZEDY Outlook After Record Sales And New FDA Progress

Teva Pharmaceutical Industries reported record quarterly UZEDY sales, with a significant year over year increase. The company raised its 2026 UZEDY revenue outlook, pointing to growing confidence in its branded product portfolio. Teva share…

Yahoo Finance hu, 30 Jul 2026

Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises

TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.

Yahoo Finance hu, 30 Jul 2026

Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

Recently published Inflammatory Bowel Disease Market Insights report includes a comprehensive understanding of current treatment practices, inflammatory bowel disease emerging drugs, market share of individual therapies, and current and for…

Yahoo Finance hu, 30 Jul 2026

Is Teva Pharmaceutical Industries (TEVA) A Bargain After Results And Higher Revenue Guidance?

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after reporting second quarter 2026 results, combining a reported net loss of US$576 million with slightly higher full year revenue guidance. See our latest analysis for Teva Pharm…

TEVA — Frequently Asked Questions

What is the current share price of TEVA?

As of 2026-08-05 17:25 PDT, TEVA trades at $34.72 on NASDAQ/NYSE. Its 52-week range is $15.38 to $36.34.

What is the market capitalisation of TEVA?

TEVA has a market capitalisation of $43.62B on NASDAQ/NYSE.

What is the P/E ratio of TEVA?

TEVA trades at a trailing price-to-earnings (P/E) ratio of 28.69. Its price-to-book (P/B) ratio is 5.51.

What is the return on equity (ROE) of TEVA?

TEVA has a return on equity (ROE) of 17.83%. Its return on capital employed (ROCE) is 14.48%.

Is TEVA a good stock to buy?

This page provides a data-driven analysis of TEVA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space